At London Valves 2022, Dr Christopher Meduri presented results from the DurAVR® THV First-in-Human study, providing preliminary echo, CT, and MRI evidence of improved hemodynamic and laminar flow characteristics associated with the DurAVR® THV System.

This prospective, non-randomized, single-arm, single-center study to evaluate the safety and feasibility of DurAVR® THV was conducted in a patient cohort of 13 subjects with severe symptomatic aortic stenosis including challenging anatomies such as Type 1 bicuspid and extreme leaflet calcium.